VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
LUCD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
LUCDLucid Diagnostics Inc.
$1.05$107M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksLUCDCash Flow

Lucid Diagnostics Inc. (LUCD) Cash Flow Statement

8Y historyFree accessUpdated daily

Free cash flow remains deeply negative with quarterly outflows frequently exceeding $10 million, necessitating a reliance on external capital to sustain operations.

LUCD Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations-46.12M-46.48B-44.14M-32.82M-29.68M-17.67M-5.63M-2.36M-113.7K
Operating CF Margin %--987781.56%-1015.65%-1351.61%-7874.01%-3533.6%---
Operating CF Growth %-23.43%-105212.64%-34.5%-10.55%-68.02%-213.89%-138.36%-1976.87%-
Net Income-45.01M-58.01B-45.53M-52.67M-56.17M-28.08M-8.28M-4.42M-1.13M
Depreciation & Amortization429.44M872M1.17M2.5M1.94M4K000
Stock-Based Compensation2.3B4.39B4.53M6.82M14.99M9.6M65K173.94K79.85K
Deferred Taxes000000000
Other Non-Cash Items23.91B6.27B119K4.85M653K04590-205.06K
Working Capital Changes-3.16M-2.81M-4.43M5.67M8.91M807K2.59M1.89M720.05K
Change in Receivables-631K-601K0-28K183K-200K000
Change in Inventory000000000
Change in Payables250K-270K96K89K-445K-665K1.15M301.85K497.23K
Cash from Investing-319K-197M-646K-221K-4.11M-862K000
Capital Expenditures-319K-197K-296K-221K-908K-862K000
CapEx % of Revenue6.21%4.19%6.81%9.1%240.85%172.4%---
Acquisitions000000000
Investments---------
Other Investing0-196.8M-350K0-3.2M0000
Cash from Financing49.08M59.03B48.25M29.46M2.61M72.08M5.58M2.5M131.5K
Debt Issued (Net)0360K18M10M00000
Equity Issued (Net)49.09M58.67M29.8M18.91M1.81M77.74M5.58M2.5M0
Dividends Paid000000000
Share Repurchases000000000
Other Financing-7K58.97B451K551K804K-5.66M00131.5K
Net Change in Cash2.64M12.35B3.46M-3.58M-31.18M53.54M-45.15K138.6K17.8K
Free Cash Flow-46.44M-46.48B-44.79M-33.04M-30.59M-18.53M-5.63M-2.36M-113.7K
FCF Margin %-904.56%-987781.56%-1030.51%-1360.71%-8114.85%-3706%---
FCF Growth %-3.9%-103693.6%-35.56%-7.99%-65.1%-229.21%-138.36%-1976.87%-
FCF per Share-0.46-455.97-0.89-0.79-0.85-0.51-0.15-0.06-0.00
FCF Conversion (FCF/Net Income)1.03x801.33x0.97x0.62x0.53x0.63x0.68x0.53x0.10x
Interest Paid000000000
Taxes Paid000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Unsustainable cash burn rate

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Disconnect Masks Cash Reality

According to the provided financial data, Lucid Diagnostics exhibits a persistent divergence between net income and operating cash flow, with OCF/NI ratios fluctuating wildly, including a notable 2.38x in 2025Q2, which suggests that non-cash charges and working capital volatility significantly distort the company's underlying earnings quality.

The lack of a stable relationship between net income and operating cash flow indicates that the company's reported losses do not fully capture the cash-intensive nature of its diagnostic operations. Investors should monitor this gap, as it suggests that accrual-based accounting may be obscuring the true magnitude of the cash required to sustain the current laboratory footprint.

Free Cash Flow Remains Deeply Negative

As reported in recent financial statements, Lucid Diagnostics has consistently generated negative free cash flow, with quarterly outflows frequently exceeding $10 million, indicating that the company's current commercialization strategy is not yet self-funding and remains entirely dependent on external capital to bridge the persistent operational deficit.

The consistent negative FCF trajectory highlights the absence of a path to self-sustainability under the current cost structure. The inability to narrow these outflows suggests that the company's expansion into test centers is currently a significant drain on liquidity rather than a driver of cash-generative growth.

Working Capital Volatility Signals Inefficiency

Based on the quarterly cash flow statements, Lucid Diagnostics has experienced erratic working capital changes, including a $1.7 million outflow in 2026Q1, which suggests that the company struggles to manage the timing of cash collections relative to the operational expenses required to support its diagnostic testing volume.

These fluctuations in working capital likely reflect the inherent difficulties in the claims-to-cash cycle for out-of-network diagnostic services. The recurring negative impact on cash flow implies that the company is effectively financing its customers' reimbursement delays, which adds further pressure to an already strained liquidity position.

Hidden Costs Obscure True Burn

As indicated by the historical cash flow data, the company's reported operating cash flow is frequently bolstered by non-cash adjustments, including stock-based compensation and depreciation, which masks the true economic cost of maintaining the laboratory infrastructure required to support the EsoGuard testing platform.

The reliance on these adjustments warrants further investigation into the actual cash cost of operations versus the accounting figures presented. It appears that the company's cash burn is structurally higher than the headline operating cash flow figures suggest, as these non-cash items do not alleviate the need for actual capital to fund ongoing laboratory operations.

LUCD — Frequently Asked Questions

Quick answers to the most common questions about buying LUCD stock.

How much cash does Lucid Diagnostics Inc. (LUCD) generate from operations?

Lucid Diagnostics Inc. (LUCD) generated $-46485.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Lucid Diagnostics Inc.'s free cash flow?

Lucid Diagnostics Inc. (LUCD) reported negative free cash flow of $46.48B in 2025, indicating capital requirements exceeded cash from operations.

What is Lucid Diagnostics Inc.'s capital expenditure (CapEx)?

Lucid Diagnostics Inc. (LUCD) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.